CHANGE IN RATINGS
upgraded at Oppenheimer to Buy. $155 price target. New analyst believes that doctors will adopt the company's technology faster than expected.
downgraded at Jefferies to Hold rating from Buy. Price target and eps estimates hold at $43 and $2.63, respectively.
upgraded at Merrill Lynch from Sell to Neutral. LBO activity is driving corporate finance activity, and the company should not post any more disappointing earnings in the near term. Estimates also raised.
upgraded at CIBC from Sector Perform to Sector Outperform. The company's focus on margins and not market share should lead to a higher long-term profitability. Second quarter estimates also cut, but the analyst also sees improvement starting in the second half of 2007. $23 price target.
upgraded at JP Morgan from Neutral to Overweight. Company is focusing on its higher margin analog business, and higher utilization rates could boost second half earnings.
upgraded at Bear Stearns from Peer Perform to Outperform. $40 price target. Positive data on Nexavar should lead to increased use for liver cancer. Estimates also raised.
upgraded from Underperform to Peer Perform at Bear Stearns. Private equity involvement raises the valuation bar. New management changes are also encouraging.
was upgraded to Outperform at Bear Stearns. Merger overhang has overly weighed on the stock, creating an attractive risk/reward level. Conservative fundamentals also support the upgrade. $4 price target.
was upgraded from Underperform to Peer Perform at Bear Stearns. Earnings could be moving higher in the near term, as SIE and HCA continue to battle.
upgraded at Wachovia to Outperform. Decision to slow down spending and focus on buybacks should be an inflection point for the stock. Estimates also boosted.
Wal-Mart was upgraded from Neutral to Overweight at JP Morgan. Stock has underperformed the SPX and TGT since Jan. 2006, but the new capital spending strategy should help increase shareholder value.
Wal-Mart upgraded at Morgan Stanley from equalweight to overweight and starts a $55 price target.
downgraded at Robert Baird from Outperform to Neutral. $15 price target. Stock has already bounced back to where it was before the latest warning. 2007 will continue to be a disappointing year.
STOCK COMMENTS / EPS CHANGES
numbers lowered at Jefferies. Price target drops to $90 from $101 and 2008 eps estimates lowered to $3.50 from $3.80. Reiterates Buy rating.
added to US 1 list at Merrill Lynch. Sum of the company's businesses are worth more than the whole, Merrill Lynch said. $86 price target. Buy rating.
was named the top pick in the energy space at Citigroup. Company has the commodity leverage, and continues to generate solid free cashflow. Market is currently discounting oil at $45 a barrel, when prices should remain closer to current levels for the time being.